Skip to main content
Fig. 2 | BMC Endocrine Disorders

Fig. 2

From: Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial

Fig. 2

Effect of treatment overtime in among treatment groups (Empagliflozin and standard care) [HBA1c (a), weight (b), BMI (c) systolic blood pressure (d), FBS (e), LDL (f), HDL (g), ALT (h), overtime in treatment groups (Empagliflozin & standard care group). Two-factor ANOVA with repeated measures analysis was performed to determine the primary safety outcomes in all patients who completed the study. P-value < 0.05 was considered as the level of significance

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us